The FDA has approved Exservan™ for the treatment of ALS
The FDA has granted early-action approval to Exservan for the treatment of ALS, which can be administered safely and easily without water.
List view / Grid view
The FDA has granted early-action approval to Exservan for the treatment of ALS, which can be administered safely and easily without water.
The FDA has handed a CRL to Biohaven for its ALS treatment awaiting approval due to concerns regarding the medication’s API.